Marché mondial des systèmes électroniques d’administration de médicaments – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse du marché et de la taille des systèmes électroniques d'administration de médicaments

L'augmentation de la prévalence des maladies ciblées est le principal facteur accélérant la croissance du marché mondial des systèmes électroniques d'administration de médicaments. En outre, le scénario de remboursement favorable sur les principaux marchés, les progrès rapides des technologies et des conceptions, l'augmentation de la prévalence de divers troubles chroniques et l'augmentation du nombre de patients gériatriques devraient également stimuler la croissance du marché des systèmes électroniques d'administration de médicaments.

Data Bridge Market Research analyse que le marché mondial des systèmes électroniques d'administration de médicaments, qui était de 16 139,89 millions USD en 2022, devrait grimper à 17 576,34 millions USD d'ici 2030 et devrait connaître un TCAC de 8,9 % au cours de la période de prévision 2023-2030. Cela indique que la valeur marchande des « pompes à perfusion électroniques » domine le segment de type du marché mondial des systèmes électroniques d'administration de médicaments en raison d'une augmentation de la demande de pompes à perfusion électroniques dans le traitement de diverses maladies chroniques. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des systèmes électroniques d'administration de médicaments

Définition du marché

Les systèmes électroniques d'administration de médicaments sont essentiellement activés électroniquement. Les dispositifs intelligents d'administration de médicaments sont bien adaptés aux soins à domicile. Ces dispositifs ajoutent de la valeur aux instruments obsolètes et augmentent la facilité d'administration, l'adéquation et la mobilité.            

Dynamique du marché mondial des systèmes électroniques d'administration de médicaments

Conducteurs

• Augmentation des maladies chroniques

La prévalence des maladies chroniques telles que le diabète, l’asthme et les maladies cardiovasculaires est en hausse dans le monde entier. Les systèmes électroniques d’administration de médicaments permettent une administration précise et contrôlée des médicaments, ce qui les rend essentiels pour gérer efficacement les maladies chroniques.

• Confort et conformité des patients

Les systèmes électroniques d'administration de médicaments offrent aux patients des options plus conviviales et pratiques pour administrer leurs médicaments. Cela peut conduire à une meilleure observance du traitement par les patients, car ces systèmes incluent souvent des rappels et des fonctions de suivi, garantissant que les patients prennent leurs médicaments comme prescrit.

• Progrès technologiques 

Advances in electronics and microtechnology have enabled the development of sophisticated electronic drug delivery devices. These devices can accurately control dosage, monitor usage, and connect with healthcare providers through mobile apps and cloud-based platforms, enhancing treatment outcomes.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Rise in Biologics and Gene Therapies

The rise of biologics and gene therapies necessitates precise and controlled drug delivery methods. Electronic drug delivery systems can play a crucial role in administering these complex therapies accurately. As the development and adoption of biologics and gene therapies increase, there is a growing opportunity for electronic drug delivery devices in this segment.

• Emerging Markets

Electronic drug delivery systems are becoming more accessible in emerging markets. As these markets continue to grow and healthcare infrastructure improves, there is a significant opportunity for companies to expand their presence and offer innovative electronic drug delivery solutions to meet the healthcare needs of these populations.

Restraints/ Challenges

• High Cost of Development and Adoption

Developing and manufacturing electronic drug delivery systems can be expensive due to the need for advanced technology, materials, and regulatory compliance. Additionally, healthcare providers and patients may face high initial costs when adopting these systems, limiting their widespread adoption, particularly in resource-constrained healthcare systems.

• Stringent Regulatory Requirements

The regulatory approval process for electronic drug delivery systems can be complex and time-consuming. Meeting the rigorous safety and efficacy standards set by regulatory authorities such as the FDA in the United States can significantly delay market entry and increase development costs.

• Limited Patient Acceptance and Training

Electronic drug delivery systems often require patients to learn how to use these devices properly. Patients, especially the elderly or those with limited technical proficiency, may be reluctant to adopt new technologies or find it challenging to use electronic drug delivery systems correctly. This can impact patient compliance and acceptance.

• Data Privacy and Security Concerns

Connected electronic drug delivery systems that transmit patient data and usage information raise concerns about data privacy and security. Healthcare providers and patients may be hesitant to use these systems if they perceive risks related to data breaches or unauthorized access to sensitive medical information.

This global electronic drug delivery systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global electronic drug delivery systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In June 2022, Gufic Biosciences Ltd launched a new drug delivery system, Dual Chamber Bags, at affordable prices for the first time in India
• In February 2022, Takeda received US FDA approval for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS), which is used to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older

Global Electronic Drug Delivery Systems Market Scope

The global electronic drug delivery systems market is segmented on the basis of type, component, connectivity, system type, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Electronic infusion pumps
• Electronic injection pens
• Electronic auto-injectors
• Electronic inhalers
• Electronic capsules
• Others

Component

• Sensors
• Wireless communicator and antennas
• Micro pumps and flow regulators
• Drug reservoir
• Microcontroller
• Others

Connectivity

• Bluetooth low energy (BLE)
• Wi-Fi
• Ethernet
• NB-IoT
• Others

System Type

• Battery-powered systems
• Rechargeable systems

Application

• Diabetes
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Multiple sclerosis
• Growth hormone therapy
• Immunodeficiency disease
• Cardiovascular disease
• Thalassemia
• Others

End User

• Hospitals
• Clinics
• Ambulatory centers
• Home healthcare
• Others

Global Electronic Drug Delivery Systems Market Regional Analysis/Insights

The global electronic drug delivery systems market is analysed and market size insights and trends are provided by country, type, component, connectivity, system type, application, and end user as referenced above.

The countries covered in the global electronic drug delivery systems market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.

North America dominates the global electronic drug delivery systems market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period 2023-2030. This is due to increment in electronic infusion pump on a large scale. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the growing incidence of asthma and heart disease with the development of the pharmaceutical industry.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.    

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global electronic drug delivery systems market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global electronic drug delivery systems market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global electronic drug delivery systems market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Electronic Drug Delivery Systems Market Share Analysis

The global electronic drug delivery systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global electronic drug delivery systems market.

Some of the major players operating in the global electronic drug delivery systems market are:

• AstraZeneca (U.K.)
• Amgen Inc. (U.S.)
• Ypsomed AG (Switzerland)
• Merck KGaA (États-Unis)
• Bayer AG (Allemagne)
• Némera (France)
• F. Hoffmann-La Roche SA (Suisse)
• Teva Pharmaceuticals USA, Inc. (États-Unis)
• AptarGroup, Inc. (États-Unis)
• Novo Nordisk A/S. (Danemark)
• ViCentra BV (Pays-Bas)
• Medtronic (États-Unis)
• United Therapeutics Corporation (États-Unis)
• Companion Medical (États-Unis)
• Tandem Diabetes Care, Inc. (États-Unis)
• Debiotech SA (Suisse)
• Canè SpA (Italie)
• Insulet Corporation (États-Unis)
• BD (États-Unis)
• B. Braun Melsungen AG (Allemagne)

SKU-50456